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 The COVID-19 pandemic has challenged all health care 
systems worldwide. Nevertheless, it is important to stress 
that there are other burdensome diseases such as influ-
enza that should also be prevented and managed. Further-
more, the coinfection of COVID-19 and influenza is a matter 
of concern among healthcare professionals and the general 
population. 
 Current public health measures implemented to avoid 
the spread of COVID-19 infection, such as social distancing 
and face masks, can also mitigate the risk of influenza in-
fection.1 While vaccines for COVID-19 are being developed 
and studied,2 we consider it is of outmost importance to em-
phasize the role of the influenza vaccine in the improvement 
of healthcare outcomes.
 According to General Directorate of Health guidelines 
(006/2019, and previous) the influenza vaccine is recom-
mended for patients at high risk of complications, includ-
ing patients with cardiovascular diseases, namely those 
with congenital heart disease, hypertensive heart disease, 
chronic heart failure, and ischemic heart disease. In this 
context, we would like to highlight the growing evidence 
regarding the benefit of the influenza vaccine in patients 
with coronary artery disease (CAD) and with heart failure 
(acknowledging that these conditions may overlap in a 
substantial proportion of patients).3
 The knowledge that respiratory infections such as influ-
enza are associated with an increased risk of acute coronary 
syndrome and exacerbation of heart failure4,5 led to studies 
evaluating the effect of vaccination in these patients, which 
were included in a recent overview of systematic reviews.3 
Data from four randomized controlled trials including 1655 
patients with CAD showed that the influenza vaccine was 
associated with a 61% risk reduction of all-cause mortality, 
56% risk reduction of cardiovascular mortality and 50% risk 
reduction of major adverse cardiovascular events (MACE).3 
Regarding heart failure patients, data from six observa-
tional studies showed a significant association between the 
influenza vaccine and decreased risk of all-cause mortality 
(17% risk reduction).3,6
 The influenza vaccine has been fully reimbursed in Por-
tugal since 2012 for individuals over 65 years old, and the 
vaccination coverage rate in this population has gone from 
43% in 2011 - 20127 to 60.8% in 2017.8 Unpublished data 
(Vacinómetro 2019/2020) shows that the vaccination cov-
erage rate may be higher than 75% in individuals over 65 
years old. This increase must be sustainable and expanded 
to the population with cardiovascular disease and age un-
der 65 years old.
 Vaccination for chronic obstructive pulmonary disease 
(COPD) patients is so well established that it is unethical 
to perform studies comparing influenza vaccine versus pla-
cebo. However, in the few studies available, the magnitude 
of risk reduction in all-cause mortality in COPD ranges from 
37% to 55% (RR 0.45 – 0.63),9 which is not as different as 
current evidence for CAD patients.
 In summary, we would like to remind physicians of the 
importance and the benefits of the influenza vaccine in pa-
tients with cardiovascular disease, regardless of age.
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